Regulatory MSD takes on Pfizer’s Prevnar with new Capvaxive approval PharmaphorumMSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 21, 2026) Pharmaphorum MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17. Infectious Disease Read full story Post navigation Previous: New biotech cAMPfield emerges with $180M to reshape IBD treatmentNext: Moderna flu vaccine wins unanimous support from FDA panel Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026